Cellular Therapies in Solid Tumors: Are We Ready for Primetime?
New FDA-approved cell therapy options for solid tumors now have practical guides for selecting patients and managing side effects, making this option real for select cancer patients.
This timely practice review synthesizes the clinical evidence and implementation frameworks for cellular therapies in solid tumors following the landmark 2024 FDA approvals of TIL and TCR therapies, detailing toxicity management and patient selection criteria relevant to practicing oncologists. The review positions ACT as an evolving but real option for select solid tumor patients, with specific guidance on early biomarker testing and specialized center referral.
What the study was
- Study design
- Practice-oriented narrative review
- Population
- N/A (review of clinical ACT data across solid tumor indications)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- JCO Oncology Practice
Why it surfaced
Practice-relevant synthesis of 2024 FDA approvals for solid tumor cellular therapies; Mayo Clinic group; JCO Oncology Practice targets practicing oncologists directly.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.